The role of TSG-6 and uroplakin III in bladder pain syndrome/ interstitial cystitis in rats and humans

Iran J Basic Med Sci. 2017 Nov;20(11):1242-1249. doi: 10.22038/IJBMS.2017.9540.

Abstract

Objectives: We investigated the relationship between the expression of tumor necrosis factor-inducible gene 6 (TSG-6) with inflammation and integrity of the bladder epithelium in the bladder tissues of patients with bladder pain syndrome/interstitial cystitis (BPS/IC) and the mechanism of action using a rat model of BPS/IC.

Materials and methods: Expression of TSG-6 and uroplakin III was determined by immuno- histochemistry of bladder biopsy samples from control human subjects and patients with verified BPS/IC. Our rat model of BPS/IC was employed to measure the perfusion of bladders with hyaluronidase, and assessment of the effect of TSG-6 administration on disease progression. Treatment effects were assessed by measurement of metabolic characteristics, RT-PCR of TGR-6 and interleukin-6, bladder histomorphology, and immunohistochemistry of TGR-6 and uroplakin III.

Results: The bladders of patients with BPS/IC had lower expression of uroplakin III and higher expression of TSG-6 than controls. Rats treated with hyaluronidase for 1 week developed the typical signs and symptoms of BPS/IC, and rats treated with hyaluronidase for 4 weeks had more serious disease. Administration of TSG-6 reversed the effects of hyaluronidase and protected against disease progression.

Conclusion: Our results indicate that TSG-6 plays an important role in maintaining the integrity of the bladder epithelial barrier.

Keywords: Bladder pain syndrome/-interstitial cystitis; Immunofluorescence – staining; Interleukin-6; TSG-6; Uroplakin III.